UPMC Physician Resources

Women Less Likely to be Academic Grand Rounds Speakers than Men

Women are less likely than men to be chosen as speakers during grand rounds, the academic mainstay of expert-delivered lectures used to share patient-care guidelines and cutting-edge research within clinical departments. Those findings by researchers at the University of Pittsburgh School of Medicine were published today in JAMA Internal Medicine.

Despite women comprising 47 percent of medical students, 46 percent of residents and 36 percent of faculty nationwide, only 26 percent of grand rounds speakers were women. Across clinical specialties, grand rounds speakers were 44 percent less likely than medical students, 39 percent less likely than residents, and 21 percent less likely than faculty to be women. Additionally, speakers invited from outside institutions were less likely to be women than those invited to speak at grand rounds from among an institution’s own personnel.

“The people at the podiums do not resemble the people in the audience,” said Julie Boiko, MD, MS, who led the study while a medical student at the Pitt School of Medicine. “While gender representation and equality in medicine has been an important area of student discussion in recent years, this is the first time we have data to support that there may be a gender bias in speaker selection at academic grand rounds.”

Data for the JAMA research letter was collected from nine major clinical specialties and 79 medical schools and academic hospitals. In total, researchers analyzed more than 200 grand rounds websites and calendar listings for speaker series, as well as more than 7,000 individual sessions for speaker gender and institutional affiliations.

As follow up to this study, researchers plan to identify specific factors associated with having greater gender balance on grand rounds speaker rosters.

“We were surprised by the consistency of this underrepresentation across most specialties and the discovery that speakers invited from outside a given institution are less likely to be women than speakers invited from within the institution,” said Alyce Anderson, coauthor of the study and an MD/PhD. candidate at the Pitt School of Medicine. “With this data, speaker planning committees, departments and institutions can strive for gender representation that approximates that of individual clinical specialties’ faculty and/or trainees. Such efforts may have a positive effect on retaining women in the academic medical workforce.”

Boiko currently is a resident physician in the Department of Pediatrics at the University of California, San Francisco. Additional coauthor Rachael Gordon is an MD/PhD student at the Pitt School of Medicine.

Thomas E. Starzl, MD, PhD, ‘Father of Transplantation,’ Dies at 90

Dr. Thomas E. Starzl, known as the “father of transplantation” for his role in pioneering and advancing organ transplantation from a risky, rare procedure to an accessible surgery for the neediest patients, died peacefully Saturday, March 4, 2017, at his home in Pittsburgh.
Dr. Starzl is survived by his wife of 36 years, Joy Starzl, of Pittsburgh, son Timothy (Bimla) of Boulder, Colorado, and a grandchild Ravi Starzl (Natalie) of Pittsburgh. He was preceded in death by a daughter, Rebecca Starzl, and a son, Thomas F. Starzl.

His family issued the following statement:

“Thomas Starzl was many things to many people. He was a pioneer, a legend, a great human, and a great humanitarian. He was a force of nature that swept all those around him into his orbit, challenging those that surrounded him to strive to match his superhuman feats of focus, will and compassion. His work in neuroscience, metabolism, transplantation and immunology has brought life and hope to countless patients, and his teaching in these areas has spread that capacity for good to countless practitioners and researchers everywhere. With determination and irresistible resolve, Thomas Starzl advanced medicine through his intuition and uncanny insight into both the technical and human aspects of even the most challenging problems. Even more extraordinary was his ability to gift that capacity to those around him, allowing his students and colleagues to discover the right stuff within themselves. Nobody who spent time with Thomas Starzl could remain unaffected.

Thomas Starzl is a globally recognized pioneer in science and medicine, but beyond that mantle, he was simply known and loved for the person that he was. He was husband and soulmate to Joy Starzl, father to Tim Starzl (Bimla), Thomas F. Starzl and Rebecca Starzl, grandfather to Ravi Starzl (Natalie), and godparent to Lamont Chatman and Angela Ford. He was deeply loved for his tremendous wit, humor and sensitivity. His traits of humility, keen observation and seemingly limitless memory fused to create a unique personality that was at the same time inspiring and comforting. His drive to always remain in motion led him on grand adventures around the world, from his beloved Colorado Rockies to the Sea of Japan, from the tundra of northern Finland to the beaches of Monaco. He had an expansive knowledge and appreciation for all music, from classical to modern jazz. He enjoyed watching and analyzing movies, often researching their production and topic matter for hours, both before and after repeated viewings. He raised and cared for many canine companions, including Bevo, Thor, Maggie, Tiki, Shelby, Basta, Chooloo and Ophelia. Their unconditional love was matched only by his own love for them. He will be greatly missed.”

Dr. Starzl joined the University of Pittsburgh School of Medicine in 1981 as professor of surgery, and led the team of surgeons who performed Pittsburgh’s first liver transplant. Thirty liver transplants were performed that year, launching the liver transplant program—the only one in the nation at the time.

Until he retired from clinical and surgical service in 1991, Dr. Starzl served as chief of transplantation services at Presbyterian University Hospital (now UPMC Presbyterian), Children’s Hospital of Pittsburgh (now Children’s Hospital of Pittsburgh of UPMC) and the Veterans Administration Hospital in Pittsburgh, overseeing the largest and busiest transplant program in the world. He then assumed the title of director of the University of Pittsburgh Transplantation Institute, which was renamed the Thomas E. Starzl Transplantation Institute in 1996. Since 1996, Dr. Starzl held the titles of Distinguished Service Professor of Surgery at the University of Pittsburgh and director emeritus of UPMC’s Thomas E. Starzl Transplantation Institute.

Dr. Starzl performed the world’s first liver transplant in 1963 and the first successful liver transplant in 1967, both while at the University of Colorado. Despite prevailing worldwide pessimism regarding the ability to transplant allogenic (non-identical) human kidneys, he successfully combined azathioprine and corticosteroids in allogenic kidney transplants performed in 1962 and 1963, leading to the largest series of kidney transplants and invigorating clinical attempts throughout the world.

In addition to developing azathioprine and corticosteroid immunosuppression, Dr. Starzl later introduced anti-lymphocyte globulin and cyclosporine to prevent organ rejection. It was this development in 1980 that advanced transplantation from an experimental procedure to an accepted form of treatment for patients with end-stage liver, kidney and heart disease. It also allowed surgeons to explore the feasibility of transplanting other organs, such as the pancreas and lung.

In 1989, Dr. Starzl announced the first-time use of FK506 (tacrolimus) as a more effective anti-rejection agent. FK506 greatly improved patient and graft survival rates for liver and other organ transplants and made intestinal transplantation possible for the first time. Five years later, FK506 was approved for clinical use by the U.S. Food and Drug Administration.

Under Dr. Starzl’s leadership, the Thomas E. Starzl Transplantation Institute also researched the feasibility of cross-species, or xenotransplantation, for addressing the chronic shortage of human organs. In 1992 and 1993, his team made history when surgeons performed two baboon-to-human liver transplants. Dr. Starzl himself performed six baboon-to-human kidney transplants in 1963 and 1964 and the world’s first chimpanzee liver xenotransplants in three children between 1969 and 1974.

A major focus of Dr. Starzl’s later research was transplant tolerance and chimerism—the existence of cells from both the donor and recipient. His work in this area offered significant contributions to the understanding of transplant immunology, particularly with respect to how and why organs are accepted.

Dr. Starzl was the recipient of more than 200 awards and honors, including the Lasker-DeBakey Clinical Medical Research Award from the Albert and Mary Lasker Foundation in 2012; the 2004 Presidential National Medal of Science, the nation’s highest scientific honor; the David M. Hume Memorial Award from the National Kidney Foundation; the Brookdale Award in Medicine presented by the American Medical Association Board of Trustees and the Brookdale Foundation; the Sheen Prize from the American College of Surgeons; the Bigelow Medal from the Boston Surgical Society; the Medallion for Scientific Achievement presented by the American Surgical Association; the William Beaumont Prize from the American Gastroenterological Association; the Peter Medawar Prize of The Transplant Society; the Jacobson Innovation Award of the American College of Surgeons; the International Chiron Award from the Italian Academy of Science; the Lannelongue International Medal from the Academie Nationale De Chirurgie (National Academy of Surgery, France); the King Faisal International Prize for Medicine from Riyadh, Kingdom of Saudi Arabia; the Rhoads Medal of the American Philosophical Society; the Prince Mahidol Award from Mahidol University at Salaya, Bangkok, Thailand; the Gustav O. Lienhard Award from the Institute of Medicine; and 26 honorary doctorates from universities around the world.

Dr. Starzl’s national and international endeavors included membership in more than 60 professional and scientific organizations. He served as president of the Transplantation Society, founding president of the American Society of Transplant Surgeons and founding president of the Transplant Recipients International Organization. In 1992, he was inducted as one of only five American members into the prestigious National French Academy of Medicine. A sought-after speaker, Dr. Starzl gave more than 1,300 presentations at major meetings throughout the world. He belonged to the editorial boards of 40 professional publications and authored or co-authored more than 2,200 scientific articles, four books and 300 book chapters.

According to the Institute for Scientific Information (ISI), Dr. Starzl for a time averaged one paper every 7.3 days, making him one of the most prolific scientists in the world. In 1999, ISI identified him as the most cited scientist in the field of clinical medicine, a measure of his work’s lasting influence and utility. The book, “1,000 Years, 1,000 People: Ranking the Men and Women Who Shaped the Millennium,” ranked Dr. Starzl 213th on its list of the 1,000 people having the greatest influence on the world in the preceding 1,000 years.

Dr. Starzl’s autobiography, “The Puzzle People: Memoirs of a Transplant Surgeon,” was published by the University of Pittsburgh Press in 1992. Translations have been published in Italian, Japanese, Korean and Spanish. All author’s royalties are donated to the Transplant Recipients International Organization.

Dr. Starzl was born March 11, 1926 in LeMars, Iowa, the son of newspaper editor and science fiction writer Rome Starzl and loving mother Anna Laura Fitzgerald.

He attended Westminster College in Fulton, Mo., where he earned his bachelor’s degree in biology. He went on to the Northwestern University Medical School in Chicago, where in 1950 he received a master’s degree in anatomy and in 1952 earned both a doctoral degree in neurophysiology and a medical degree with distinction.

Following postgraduate work at Johns Hopkins Hospital in Baltimore, Dr. Starzl pursued his interest in surgery and research with a fellowship and residencies at Johns Hopkins, the University of Miami and the Veterans Administration Research Hospital in Chicago. He was a Markle Scholar in Medical Science, a distinguished honor bestowed annually to a small group of exceptionally promising young physicians in academic medicine. Dr. Starzl served on the faculty of Northwestern University from 1958 to 1961 and joined the University of Colorado School of Medicine as an associate professor in surgery in 1962. He was promoted to professor in 1964 and served as chairman of the department of surgery from 1972 to 1980.

Regarding Dr. Starzl:
“Tom Starzl was a man of unsurpassed intellect, passion and courage whose work opened up a new frontier in science and forever changed modern medicine. He will be remembered for many things, but perhaps most importantly for the countless lives he saved through his pioneering work. We at Pitt have lost a friend and colleague who took the University to new heights of recognition and achievement — Patrick Gallagher, Chancellor, University of Pittsburgh

“Dr. Starzl’s pioneering work in organ transplantation set the standard for innovation and excellence at UPMC. An extraordinarily skilled and compassionate surgeon and brilliant researcher, he brought hope to the sickest of the sick, a legacy that we continue to build on today.” — Jeffrey A. Romoff, President and CEO, UPMC

“Tom Starzl’s tremendous respect and affection for his patients became the life force of his career. Countless lives were saved through his advances in technique and his pioneering work to prevent organ rejection. There is not a transplant surgeon worldwide who has not, in some way, been influenced by his work.” — Arthur S. Levine, MD, University of Pittsburgh Senior Vice Chancellor for the Health Sciences and John and Gertrude Petersen Dean of the University of Pittsburgh School of Medicine

“Tom Starzl devoted his life to the cause of human health and advanced the field of medicine in ways that were unimaginable to most. He applied a combination of extraordinary talent and steely determination to build an unparalleled record of impact as a uniquely gifted surgeon, a visionary researcher, a prolific scholar and the single most influential teacher in the ground-breaking field of organ transplantation. In the process, he became a hero to countless transplant patients, their families and their physicians, while also playing a key role in the elevation of Pitt and in the transformation of Pittsburgh.” — Mark A. Nordenberg, Chancellor Emeritus, University of Pittsburgh

“Words cannot convey how deeply saddened we all are with the passing of Dr. Starzl. It’s impossible to quantify the magnitude of his contributions to the field of transplant. I feel so deeply honored and privileged to have had the opportunity to know him personally over the last few years. The world has lost today the greatest figure in the history of transplant, and I have lost my greatest mentor. The Starzl Transplant Institute will continue to work tirelessly to carry on his rich legacy.” — Dr. Abhinav Humar clinical director of the Thomas E. Starzl Transplantation Institute and chief of the Division of Transplantation in the Division of Surgery at UPMC

Physicians and Researchers Present at the American College of Cardiology (ACC) 66th Annual Scientific Session

The UPMC Heart and Vascular Institute will be well-represented at the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington, DC. Faculty research will be featured in both oral and poster presentations throughout the conference, including:

 

Friday, March 17

Session 1120: Novel Echocardiographic Methods for Assessing Cardiac Function

Racial Differences in Left Ventricular Recovery in Patients With Peripartum Cardiomyopathy Assessed by Global Longitudinal Strain

Presented by: Masataka Sugahara, Dennis McNamara, Joan Briller, Leslie Cooper, Julie Damp, Mark H. Drazner, James Fett, Eileen Hsich, Navin Rajagopalan, John Gorcsan

 

Session 1130: Innovations in Practice Management and Social Media

Formal CPR Status Policy and Process Increased Documentation Rates

Presented by: Joshua E. Levenson, Aken Desai, Karen Kelly, Emilie Prout, Joon Lee, Mark Schmidhofer, Winifred Teuteberg

 

Session 1149: Arrhythmias and Clinical EP: Devices 2

Persistent Gender Disparities in Implantable Cardioverter-Defibrillator Therapy

Presented by: Amber E. Johnson, Shubash Adhikari, Andrew Althouse, Floyd Thoma, Oscar Marroquin, Stephen Koscomb, Leslie Hausmann, Larissa Myaskovsky, Samir Saba

 

Session 1150: Arrhythmias and Clinical EP: AF Ablation

Characterization of Pulmonary Vein Reconnection Post Cryoballoon Ablation

Presented by: Shivang Shah, Wenjie Xu, Evan Adelstein, Andrew Voigt, Samir Saba, Sandeep Jain

 

Session 1157: Complex Coronary Intervention: Left Main/Bifurcations and Multivessel Disease

Multivessel Versus Culprit-Only PCI in Patients With Non-ST Segment Elevation Myocardial Infarction and Multivessel Disease: Results From the PROMETHEUS Study

Presented by: Birgit Vogel, Usman Baber, Samantha Sartori, Jaya Chandrasekhar, Serdar Farhan, Michela Faggioni, Sabato Sorrentino, Annapoorna Kini, William Weintraub, Sunil Rao, Samir Kapadia, Sandra Weiss, Craig Strauss, Catalin Toma, J. Muhlestein, Anthony C. DeFranco, Mark Effron, Stuart Keller, Brian Baker, Stuart Pocock, Timothy Henry, Roxana Mehran

 

Session 4101: Advanced heart Failure and VAD Therapy
Presented by: Jeffrey Teuteberg

 

Saturday, March 18

Session 904: Highlighted Original Research: Pulmonary Hypertension and Venous Thrombo-embolic Disease and the Year in Review

Simplified Measures of Right Ventricular and Atrial Remodeling Are Predictive of Outcomes in Patients With Pulmonary Hypertension

Presented by: Masataka Sugahara, Keiko Ryo-Koriyama, Akiko Goda, Omar Batal, Marc Simon, John Gorcsan

 

Session 1196: Nuclear Cardiology: Beyond Perfusion

Regional Right Ventricular (RV) Function as Determined by Gated Blood Pool SPECT (GBPS) Provides Additive Value to Evaluation of Patients Undergoing Left Ventricular Assist Device (LVAD) Implantation

Presented by: Christopher B. Link, Aditi Nayak, Robert Kormos, Marc Simon, Jeffrey Teuteberg, Luigi Lagazzi, Andrew Althouse, Prem Soman

 

Session 1201: Advances in HCM, PPCM and Other Cardiomyopathies

Extended Course of Recovery in Patients With Peripartum Cardiomyopathy Assessed by Left Ventricular Wall Distensibility

Presented by: Masataka Sugahara, Dennis McNamara, Lori Blauwet, Rami Alharethi, Paul Mather, Kalgi Modi, Richard Sheppard, Vinay Thohan, Gretchen Wells, John Gorcsan

 

Session 669: Distinct Phenotypes in HFpEF: Beyond Ejection Fraction

669-03 – Diagnostic Evaluation of Patients with Dyspnea and Normal LVEF
Presented by: John Gorcsan

 

Session 1226: Put Your Codon! Genetic Insights Into Heart Failure

G-Protein Receptor Kinase 5 Polymorphisms and Outcomes in the African American Heart Failure Trial: Results From the Genetic Risk Assessment of Heart Failure in African-Americans Sub-Study

Presented by: Amber E. Johnson, Karen Hanley-Yanez, Clyde Yancy, Anne Taylor, Arthur Feldman, Dennis McNamara

 

Session 1242: Timely Topics in Acute Coronary Syndromes

Use of Potent P2y12 Inhibitors in African-American Patients Treated With Percutaneous Coronary Intervention for Acute Coronary Syndromes

Michela Faggioni, Usman Baber, Jaya Chandrasekhar, Birgit Vogel, Samantha Sartori, Melissa Aquino, Annapoorna Kini, William Weintraub, Samir Kapadia, Sandra Weiss, Craig Strauss, Clayton Snyder, Catalin Toma, J. Muhlestein, Anthony C. DeFranco, Mark B. Effron, Stuart Keller, Brian Baker, Stuart Pocock, Timothy Henry, Sunil Rao, Roxana Mehran

 

Session 1257: FIT Clinical Decision Making: Heart Failure and Pulmonary Hypertension

1257-408 / 408 – When the Liver Gets Sacked by the Heart Sac: A Diagnostic Challenge of Mixed Heart and Liver Pathology
Presented by: Ahmad Masri, John Gorcsan

 

Session 1245: New Technologies in Echocardiography

1245-219 / 219 – Assessment of Right Ventricular Energy Loss and Efficiency Using Novel Vector Flow Mapping

Presented by: Masataka Sugahara, Nina Hasselberg, Marc Simon, John Gorcsan

 

Session 1246: Nuclear Cardiology: Quality

Repeatability of Appropriateness Category Allocation by Trained Physicians

Presented by: Daniel Nguyen, Aditi Nayak, Christopher Pray, Christopher Link, Andrew Althouse, Prem Soman

 

Session 702: The Forgotten Chamber: The Right Ventricle in Heart Failure

RV Failure After LVAD: Predictable and Preventable?
Presented by: Jeffrey Teuteberg

 

Session 1235: Innovations in Cardiovascular Risk Assessment and Reduction

Ideal Cardiovascular Health Metrics in Couples: A Community-Based Population Study

Presented by: Oluremi Ajala, Sebhat Erqou, Claudia Bambs, Michael Sharbaugh, Andrew Althouse, Aryan Aiyer, Kevin Kip, Steven Reis

 

Session 1230: Predicting the Future: Observations and Discoveries From Registries and Databases

Pulmonary Vascular Resistance Predicts Mortality in End-Stage Renal Disease Patients With Pulmonary Hypertension

Presented by: Jonathan Wolfe, Gavin Hickey, Andrew Althouse, Michael Sharbaugh, Deepak Kumar Pasupula, Dustin Kliner, Michael Mathier, Prem Soman

 

Session 727: Aortic Stenosis: Overview of the Hemodynamics and Ventricular Response

Expanding the Diagnostic Toolbox for Aortic Stenosis
Presented by: João Cavalcante

 

Session 716: Pregnancy and Heart Disease

Peripartum Cardiomyopathy – Long term Outcomes and Management Options
Presented by: Dennis McNamara

 

Session 4103: Advanced Heart Failure and VAD Therapy
Presented by: Jeffrey Teuteberg

 

Sunday, March 19

Session 732: Nuclear Cardiology: Current Applications and Best Practices: Joint Symposium of the American Society of Nuclear Cardiology and the American College of Cardiology

Nuclear Cardiology: Risk Stratification
Presented by: Prem Soman

 

Session 738: Controversies in Mitral Valve Surgery: Joint Symposium of the Society of Thoracic Surgeons and the American College of Cardiology

What to do if the left ventricle fails after mitral valve surgery
Presented by: Robert Kormos

 

Session 770: Great Debates in Cardiac MRI

Debate Con: Stress MRI is the Test of Choice for Ischemia Assessment
Presented by: Prem Soman

 

Session 4105: Advanced Heart Failure and VAD Therapy
Presented by: Jeffrey Teuteberg

 

Session 1274: The Challenges of Outcome Prediction in Valvular Heart Disease

Poor Agreement Between Transthoracic Echocardiography and Right Heart Catheterization for Assessment of Pulmonary Hypertension Severity: Clinical Applications in the TAVR Era

Presented by: Islam Abdelkarim, Jeffrey Xu, Michael Sharbaugh, Andrew Althouse, William Katz, Frederick Crock, Matthew Harinstein, Dustin Kliner, Forozan Navid, Joon Lee, John Schindler, Thomas Gleason, João Cavalcante

 

Session 1282: Advances in Chronic Total Occlusion Intervention

The Impact of Epicardial Collateral Use on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry

Presented by: Judit Karacsonyi, Khaldoon Alaswad, Farouc Jaffer, Robert Yeh, Dimitrios Karmpaliotis, Jeffrey Moses, Ajay Kirtane, Manish Parikh, Ziad Ali, David Kandzari, Nicholas Lembo, William Lombardi, R. Michael Wyman, Anthony Doing, Catalin Toma, James Choi, Mitul Patel, Ehtisham Mahmud, Barry Uretsky, Aris Karatasakis, Bavana Rangan, Imre Ungi, Craig Thompson, Subhash Banerjee, Emmanouil Brilakis

 

Session 1307M: Emerging Applications for Imaging Cardiac Amyloidosis: Nuclear Cardiology

Predictors of a Positive Technetium Pyrophosphate Scan in Patients With Suspected Cardiac Amyloidosis

Presented by: Ahmad Masri, Ricardo Nieves, Michael S. Sharbaugh, Andrew Althouse, William Follansbee, João Cavalcante, Prem Soman

 

Session 1221M: TAVR outcomes Prognostication

Prognostic Value of Right Ventricle-Pulmonary Artery Coupling in TAVR Patients: Time to Integrate the Right Side Unit

Presented by: João Cavalcante, Islam Abdelkarim, Michael Sharbaugh, Andrew Althouse, Jeffrey Xu, Wei Han, William Katz, Frederick Crock, Matthew Harinstein, Dustin Kliner, Forozan Navid, Joon Lee, John Schindler, Thomas Gleason

 

Session 769: Life After LVAD: The Good, The Bad and The Ugly

Right Ventricular Failure After LVAD
Presented by: Robert Kormos

 

Session 785: Radiation from Diagnostic Imaging: Risk-benefit Analysis
Panelist: Prem Soman

UPMC Updates in Otolaryngology: A Monthly Webinar Series

ent-webinar-series_880x135

 

 

The UPMC Department of Otolaryngology presents a free webinar series — UPMC Updates in Otolaryngology.

Upcoming webinars include:

September 6, 2016 – 8 p.m.: Update in Unilateral Vocal Cord Paralysis
Presented by:Clark Rosen, MD — Professor, Department of Otolaryngology
Moderated by: David Eibling, MD — Professor, Department of Otolaryngology

Archived webinar, now available for free CME: http://www.upmcphysicianresources.com/cme-course/update-in-unilateral-vocal-fold-paralysis

October 4, 2016 – 8 p.m.: Gulp! Helping People with Dysphagia
Presented by: Libby Smith, DO — Associate Professor, Department of Otolaryngology
Moderated by: Jonas Johnson, MD, FACS — Professor and Chairman, Department of Otolaryngology

Archived webinar, now available for free CME: http://www.upmcphysicianresources.com/cme-course/gulp-helping-people-with-dysphagia

November 15, 2016 – 8 p.m.: Nasal Airway Obstruction: Maximizing the Yield of the Clinical Exam
Presented by: Grant Gillman, MD, Associate Professor – Department of Otolaryngology
Moderated by: Summan Golla, MD, Associate Professor – Department of Otolaryngology

Archived webinar, now available for free CME: http://www.upmcphysicianresources.com/cme-course/nasal-airway-obstruction-maximizing-the-yield-of-the-clinical-exam

December 6, 2016 – 8 p.m.: Tinnitus Retraining Therapy: How to Live with the Sounds
Presented by: Lori Zitelli, AuD, CCA-A
David Eibling, MD — Professor, Department of Otolaryngology

January 10, 2017 – 8 p.m.: Evaluation of Noisy Breathing in Infants and Children
Presented by: Jeffrey Simons, MD — Associate Professor, Department of Pediatric Otolaryngology
Moderated by: Jonas Johnson, MD, FACS — Professor and Chairman, Department of Otolaryngology

February 7, 2017 – 8 p.m.: Update in Implantable Hearing Devices
Presented by: Barry Hirsch, MD — Professor, Department of Otolaryngology
Moderated by: Jonas Johnson, MD, FACS — Professor and Chairman, Department of Otolaryngology

March 7, 2017 – 8 p.m.: Neurostimulation Therapy for Obstructive Sleep Apnea
Presented by: Ryan Soose, MD — Assistant Professor, Department of Otolaryngology
Moderated by: Bridget Hathaway, MD — Assistant Professor, Department of Otolaryngology

Archived webinar, now available for free CME: http://www.upmcphysicianresources.com/cme-course/neurostimulation-of-the-upper-airway-star-trial-and-upmc-clinical-update

April 4, 2017 – 8 p.m.: Update on Sino-Nasal Malignancy
Presented by: Eric Wang, MD — Associate Professor, Department of Otolaryngology
Moderated by: David Eibling, MD — Professor, Department of Otolaryngology

May 9, 2017 – 8 p.m.: Advances and Novel Therapeutics in the Treatment of Chronic Rhinosinusitis
Presented by: Stella Lee, MD — Associate Professor, Department of Otolaryngology
Moderated by: TBD

June 6, 2017 –8 p.m.: Advances in Management of Oropharynx Cancer: HPV, Robotic Surgery, and Immunotherapy
Presented by: Robert Ferris, MD, PhD — Associate Professor, Department of Otolaryngology
Moderated by: Barry Schaitkin, MD, FACS — Professor, Department of Otolaryngology

For more information, to register for a webinar, or to view all past webinars, visit the Chorus Call website.

UPMC Department of Otolaryngology Launches Head and Neck Cancer Survivorship Program

The UPMC Department of Otolaryngology recognizes that cancer survivorship starts at diagnosis.  The multidisciplinary providers of UPMC’s Head and Neck Cancer Survivorship Clinic offer a comprehensive evaluation to patients before the start of their cancer treatment. This evaluation allows us to not only identify underlying issues patients may be experiencing regarding swallowing, dental care, and mobility, but also allows us to educate patients about strategies to optimize their health during treatment.  After treatment, we utilize a patient-centered approach that includes surveillance, assessment of treatment effects, identification of referral and resources to help our survivors live beyond their cancer.

For more information about patient referral, call 412-647-2100.

Children’s Hospital of Pittsburgh of UPMC Ranked Highest in the US for Liver Transplant Outcomes

PrintThe Hillman Center for Pediatric Transplantation at Children’s Hospital of Pittsburgh of UPMC is ranked highest in the United States for pediatric liver transplant outcomes, according to January data released from the Scientific Registry of Transplant Recipients (SRTR).

The SRTR, which manages and analyzes a wide range of transplant data as a service to the public, noted several achievements for Children’s in 2017. When comparing hazard ratio estimates, Children’s ranks as No. 1 out of 62 pediatric liver transplant centers in the U.S. in one-year overall patient survival as well as one-year overall graft survival.

Of the 29 centers performing pediatric living-donor liver transplants, Children’s hazard ratio estimates also rank first in one-year patient and graft survival, as well as three-year patient and graft survival. Children’s has performed over 135 living-donor liver transplants since 1997, and more than any pediatric transplant center in the last five years nationally.

The hazard ratio provides an estimate on how the results at Children’s compare with what was expected based on modeling the transplant outcomes from all U.S. programs. Based on the characteristics of patients transplanted at Children’s from July 2013 through December 2015, SRTR hazard ratio results indicate a 59 percent estimated lower risk of patient mortality and a 76 percent estimated lower risk of graft failure when compared to other pediatric liver transplant centers.

“This new data exemplifies the extraordinary talent and skill our surgeons, hepatologists and entire transplant team bring to hopeful patients and families around the world,” said George Mazariegos, MD, chief, pediatric transplantation at Children’s. “Our decades of experience are unparalleled—we have performed more pediatric liver transplants than any other center in the United States while achieving patient survival rates that are consistently among the best.”

Children’s has performed more than 1,700 pediatric liver transplants since the program’s inception in 1981 through December 2016. This includes:
•    70-plus transplants in children and young adults with maple syrup urine disease—more than any other center in the U.S., while achieving 100 percent patient and graft survival.
•    330-plus transplants for children and young adults with metabolic liver disease—more than any other transplant center, including adult facilities.
•    135-plus living-donor liver transplants since 1997. In the last five years of recorded data (2011 to 2016), Children’s has performed more living-donor liver transplants than any other pediatric liver transplant center in the country.
•    18 domino liver transplants—more than any other center in the nation, while achieving 100 percent patient and graft survival.

Children’s also is the first and only pediatric transplant center in the nation to expand the geographic reach of its program through a partnership with the University of Virginia Children’s Hospital in Charlottesville.

For more information about the pediatric liver transplant program at the Hillman Center for Pediatric Transplantation at Children’s, please visit www.chp.edu/livertransplant.

2017 AAP Annual Meeting — Feb. 7-11, Las Vegas, NV

The UPMC Department of Physical Medicine and Rehabilitation will be well represented at the 2017 AAP Annual Meeting in Las Vegas Feb. 7-11.  Several experts from the department will lead discussions and present posters during this five day conference, including a seminar by Gwendolyn Sowa, MD, PhD, Professor and Chair, Department of Physical Medicine and Rehabilitation. Dr. Sowa’s seminar will take place Thursday, Feb. 9, from 12:30 to 5:30 p.m. on the topic of Women  in Academic Physiatry: Pearls in Career Development

Awards

Shanti Pinto, MD, brain injury medicine fellow, will receive the Association of Academic Physiatrists‘ Best Paper Award for “Cost-Efficacy Analysis of Routine Venous Doppler Ultrasound for Diagnosis of Deep Venous Thrombosis at Admission to Inpatient Rehabilitation.” The award recognizes and seeks to encourage young researchers, while strengthening all investigation in the field of PM&R.

Joshua Rothenberg, DO, sports medicine fellow, will be awarded the McLean Outstanding Fellow Award from the Association of Academic Physiatrists. The award recognizes an AAP member fellow for outstanding academic performance in academic leadership, teaching and education, and research. Dr. Rothenberg will receive the award during the AAP Annual Meeting in February 2017.

To view a full list of UPMC presentations and presenters, click here and here.

 

Announcing Our New Co-Director of the Inflammatory Bowel Disease (IBD) Center — Sandra Kim, MD, Children’s Hospital of Pittsburgh of UPMC

PrintSandra Kim, MD, a nationally recognized expert in pediatric and adolescent inflammatory bowel disease, is the co-director of the Inflammatory Bowel Disease (IBD) Center, a part of the Division of Pediatric Gastroenterology, Hepatology, and Nutrition at Children’s Hospital of Pittsburgh of UPMC. Dr. Kim is also Associate Professor of Pediatrics at the University of Pittsburgh School of Medicine. Prior to joining Children’s Hospital, Dr. Kim was co-director of the Center for Pediatric and Adolescent Inflammatory Bowel Disease at Nationwide Children’s Hospital in Columbus, Ohio.

In Pittsburgh, Dr. Kim, along with Sapana Shah, MD, will establish the hospital’s participation in Improved Care Now, a national consortium to improve the care of children with IBD. Dr. Kim’s clinical and research interests focus on pediatric inflammatory bowel diseases, including adolescent transitioning and quality improvement in pediatric IBD and the impact of the gastrointestinal microbiota in IBD. Her research has been funded by the National Institutes of Health and the Crohn’s and Colitis Foundation of America (CCFA). She has authored numerous studies on pediatric and adolescent inflammatory bowel diseases. Dr. Kim currently serves as past chair of Pediatric Affairs and current co – chair of Government Affairs/Advocacy for the CCFA nationally. In addition, she chairs the Clinical Practice and Adolescent Transitioning committees and serves on the Physician Leadership committee and Strategy Council for Improve Care Now. Dr. Kim also is involved as a member of the Medical Advisory Board for Flying Horse Farms and on the board of Directors for the Central Ohio CCFA chapter. As a reflection of her dedication to her profession, Dr. Kim was awarded the 2011 Rosenthal Award for her leadership in patient education and advocacy by the CCFA. She also was the 2015 faculty inductee at the Ohio State University College of Medicine chapters of Gold Humanism Honor Society and Alpha Omega Alpha.

Dr. Kim is a graduate of the University of Michigan’s Inteflex (Integrated Pre-medical/Medical) Program, earning bachelors’ degrees in Biomedical Sciences and Psychology as well as her medical degree. She completed clinical training in General Pediatrics and Pediatric Gastroenterology at Texas Children’s Hospital and the Baylor College of Medicine. She was a recipient of the Outstanding Clinical Fellow Award during her GI fellowship and was on the NIH/NIDDK-funded T32 grant for her research project investigating zinc metabolism in children with IBD. After her clinical training, she pursued additional training as a post-doctoral fellow at the NIH-funded Center for GI Biology and Disease at the University of North Carolina at Chapel Hill.

American Academy of Pediatrics Webinar Series on Zika Virus featuring Amy Houtrow, MD, PhD — Jan. 10, 2017

Recognizing Microcephaly and Other Presentations of Zika Virus Syndrome
Tuesday, Jan. 10, 2 p.m. ET
Registration is required.

Dial-In Information
Phone: 844-216-1726
Conference ID: 18985179
Registration Link: https://cc.readytalk.com/r/viw68r9pls12&eom

Description
Over the past year, congenital Zika virus syndrome has captured the attention of the world because of the devastating effects it can have on infants’ development. In recognition that pediatricians (primary care providers, clinicians, and subspecialists) will require support and guidance, the American Academy of Pediatrics Webinar Series on Zika Virus Syndrome was created. During the first webinar in this series, expert speakers will provide an overview of the neurodevelopmental manifestations of congenital Zika virus syndrome. Experts will also describe how to monitor symptomatic and asymptomatic infants, including how to collaborate with specialists to ensure a continuum of care.

Speakers
Amy Houtrow, MD, PhD, MPH, FAAP
Dr Houtrow is pediatric rehabilitation medicine physician and health services researcher.  She is an Associate Professor and Vice Chair in the Department of Physical Medicine and Rehabilitation for Pediatric Rehabilitation Medicine at the University of Pittsburgh School of Medicine. She directs the Pediatric Rehabilitation Medicine Fellowship and is the Chief of Pediatric Rehabilitation Medicine Services and the Medical Director of the Rehabilitation Institute at the Children’s Hospital of Pittsburgh. Dr Houtrow’s main clinical focus is caring for children with disabling conditions to help to improve functioning and quality of life to the greatest degree possible. Her research focuses on improving how children with disabilities and their families access health care to optimize health care delivery.

Edwin Trevathan, MD, MPH, FAAP
Dr. Trevathan is a child neurologist, an epidemiologist, and a public health leader, who is internationally known for his expertise in childhood epilepsy, disorders of the developing brain, developmental disabilities, and birth defects. Trevathan is a Professor of Pediatrics and Neurology at Vanderbilt University School of Medicine, and a pediatric neurologist at the Monroe Carell Jr. Children’s Hospital at Vanderbilt. Dr Trevathan has held a number of senior leadership positions in academia and in government. He has served as Executive Vice President and Provost at Baylor University; Dean of the College for Public Health and Social Justice at Saint Louis University; Director of the Division of Pediatric and Developmental Neurology at Washington University in St. Louis, MO; and Director of the National Center on Birth Defects and Developmental Disabilities at the Centers for Disease Control and Prevention.

Additional Information
Please email DisasterReady@aap.org with any questions prior to the webinar.

 

 

Reducing the Duration of Antibiotics Does More Harm than Good When Treating Ear Infections in Young Children

PrintIn a landmark trial conducted at Children’s Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine, researchers have demonstrated that when treating children between 6 and 23 months of age with antibiotics for ear infections, a shortened course has worse clinical outcomes without reducing the risk of antibiotic resistance or adverse events.

The results of the trial are published today in the New England Journal of Medicine and highlighted by an accompanying commentary.

Acute otitis media is a bacterial infection of the middle ear behind the ear drum which causes it to become painfully inflamed. Three out of four children experience this infection within their first year. Consequently, it is the most common reason why children are prescribed an antibiotic.

“Given significant concerns regarding overuse of antibiotics and increased antibiotic resistance, we conducted this trial to see if reducing the duration of antibiotic treatment would be equally effective along with decreased antibiotic resistance and fewer adverse reactions,” said Alejandro Hoberman, MD, chief, Division of General Academic Pediatrics at Children’s, and the Jack L. Paradise Endowed Professor of Pediatric Research at Pitt’s School of Medicine.

In the current trial, 520 children with acute otitis media were randomly assigned to either a standard 10-day regimen of the antibiotic amoxicillin-clavulanate or a shortened 5-day treatment followed by five days of placebo. Neither the study participants nor the physicians knew which group the participant was assigned to.

Children were followed starting in October through the rest of the annual respiratory-infection season, and had a final visit during the following September.

They found that the risk of treatment failure in the 5-day group (34 percent) was more than twice as much the risk in the 10-day group (16 percent). The results were significant when considering the trial design which was set up to find out whether the 5-day treatment would be as good as the 10-day regimen, Dr. Hoberman said. Instead, the results clearly showed that not only was their initial assumption proven wrong, but the 10-day treatment was far more effective.

When they tested the presence of antibiotic-resistant bacteria through nasopharyngeal (back of the nose) swabs, there was no decrease in the 5-day group as might have been expected with a shorter duration of antibiotics. Also, reduced-duration antibiotics did not decrease the risk of frequent adverse events like diarrhea or diaper rash.

When testing the risk of a recurrent infection, they found that it was higher when children were exposed to three or more children for 10 or more hours per week, such as in a day care setting, or if the initial infection occurred in both ears as opposed to just one ear.

Importantly, the study also showed for the first time that almost one in two children in whom residual fluid was observed in the middle ear after treatment had a recurring infection, a significantly higher percentage when compared to children without any residual fluid in the middle ear.

The marked superiority of the 10-day regimen over the 5-day regimen led the independent safety monitoring board overseeing the trial to conclude it prematurely as the primary end point was achieved.

“The results of this study clearly show that for treating ear infections in children between 6 and 23 months of age, a 5-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance. Though we should be rightly concerned about the emergence of resistance overall for this condition, the benefits of the 10-day regimen greatly outweigh the risks,” said Dr. Hoberman.

The study was supported by a contract (HHSN272201000047C) from the National Institute of Allergy and Infectious Diseases and by University of Pittsburgh Clinical and Translational Science Awards (UL1RR024153 and UL1TR000005) from the National Center for Research Resources, now at the National Center for Advancing Translational Sciences, National Institutes of Health.

Other authors include Jack L. Paradise, MD, Howard E. Rockette, PhD, Diana H. Kearney, RN, CCRC, Sonika Bhatnagar, MD, MPH, Timothy R. Shope, MD, MPH, Judith M. Martin, MD, Marcia Kurs-Lasky, MS, Susan J. Copelli, BS, D. Kathleen Colborn, BS, Stan L. Block, MD, John J. Labella, MD, Thomas G. Lynch, MD, Norman L. Cohen, MD, MaryAnn Haralam, CRNP, Marcia A. Pope, RN, Jennifer P. Nagg, RN, Michael D. Green, MD, MPH, and Nader Shaikh, MD, MPH, all from Children’s Hospital of Pittsburgh of UPMC and the University of Pittsburgh.

Learn more about Shorter Antibiotic Treatment for Otitis Media from The New England Journal of Medicine.

Page 2 of 80:« 1 2 3 4 5 »Last »